… our preclinical proof of concept data for the platform, a partnership with Eli Lilly, a leading IP position, and strong … and pipeline programs. Continue to execute on existing partnership with Eli Lilly and Company (Lilly). ProQR may selectively form new partnerships, which could include multi-target discovery …
… continues to execute on its global licensing and research partnership with Eli Lilly, focused on the discovery, … and nervous system, and may selectively enter additional partnerships designed to advance and capture the full … continue to execute on our global licensing and research partnership with Eli Lilly and may selectively enter into …
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical cataly
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre
… to progress well and we are pleased to be expanding our partnership to include additional targets, along with an … “Lilly is a leader in RNA therapeutics, and our expanded partnership is another validation of our leadership in … the ability to exercise an option to further expand the partnership for a consideration of $50 million. In addition, …
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort